Skip to main content

Table 6 Costs distribution according to scenario 1 to 4 from the societal perspective

From: Valuing the cost of improving Chilean primary vaccination: a cost minimization analysis of a hexavalent vaccine

 Unitary cost (US$)AmountTotal (US$)
Scenario 1
 Hexavalent (DTaP-IPV-HepB-Hib) vaccine19.80997,87719,757,965
 Pentavalent (DTwP-Hib-HepB) vaccine2.85966,9332,754,539
 Average IPV (1) + bOPV (3) = 3.6 + (0.32*3) = 4.51.14966,9331,102,304
 Difference of schemes15.81966,93315,288,431
 Additional costs of the simultaneous scheme  8,838,805
 Cost to society  6,449,627
Scenario 2
 Hexavalent (DTaP-IPV-HepB-Hib) vaccine19.80997,87719,757,965
 Pentavalent (DTwP-Hib-HepB) vaccine2.85966,9332,754,539
 IPV four doses- average = 3.603.6966,9333,480,959
 Difference of schemes13.35966,93312,909,776
 Additional costs of the simultaneous scheme  8,838,805
 Cost to society  4,070,971
Scenario 3
 Hexavalent (DTaP-IPV-HepB-Hib) vaccine19.80997,87719,757,965
 Pentavalent (DTwP-Hib-HepB) vaccine2.85966,9332,754,539
 IPV four-dose bottle plus syringe = 2.102.10966,9332,030,559
 Difference of schemes14.85966,93314,360,176
 Additional costs of the simultaneous scheme  8,838,805
 Cost to society  5,521,371
Scenario 4
 Hexavalent (DTaP-IPV-HepB-Hib) vaccine19.80997,87719,757,965
 Pentavalent (DTwP-Hib-HepB) vaccine2.85966,9332,754,539
IPV four doses- pre-filled syringe = 5.105.10966,9334,931,358
 Difference of schemes11.85997,87711,459,377
 Additional costs of the simultaneous scheme  8,838,805
 Cost to society  2,620,572
  1. bOPV bivalent oral polio vaccine, IPV inactivated polio vaccine